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ChemotaxisSeveral studies have pointed out the immunomodulatory properties of the Salivary Gland Extract (SGE) from
Lutzomyia longipalpis. We aimed to identify the SGE component (s) responsible for its effect on ovalbumin
(OVA)-induced neutrophil migration (NM) and to evaluate the effect of SGE and components in the
antigen-induced arthritis (AIA) model. We tested the anti-arthritic activities of SGE and the recombinant
LJM111 salivary protein (rLJM111) by measuring the mechanical hypernociception and the NM into synovial
cavity. Furthermore, we measured IL-17, TNF-α and IFN-γ released by lymph nodes cells stimulated with
mBSA or anti-CD3 using enzyme-linked immunosorbent assay (ELISA). Additionally, we tested the effect of
SGE and rLJM111 on co-stimulatory molecules expression (MHC-II and CD-86) by ﬂow cytometry, TNF-α
and IL-10 production (ELISA) of bone marrow-derived dendritic cells (BMDCs) stimulated with LPS, chemo-
taxis and actin polymerization from neutrophils. Besides, the effect of SGE on CXCR2 and GRK-2 expression
on neutrophils was investigated. We identiﬁed one plasmid expressing the protein LJM111 that prevented
NM in OVA-challenged immunizedmice. Furthermore, both SGE and rLJM111 inhibited NM and pain sensitivity
in AIA and reduced IL-17, TNF-α and IFN-γ. SGE and rLJM111 also reduced MHC-II and CD-86 expression and
TNF-α whereas increased IL-10 release by LPS-stimulated BMDCs. SGE, but not LJM 111, inhibited neutrophils
chemotaxis and actin polymerization. Additionally, SGE reduced neutrophil CXCR2 expression and increased
GRK-2. Thus, rLJM111 is partially responsible for SGE mechanisms by diminishing DC function and maturation
but not chemoattraction of neutrophils.
© 2012 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
It has been shown that salivary gland extract (SGE) from Lutzomyia
longipalpis enhances Leishmania infection inmice [1] not by a direct effect
on the parasite virulence but rather by affecting host immune defenses
[2–4]. SGE contains a variety of potent pharmacologically active sub-
stances that interferewith host homeostatic, inﬂammatory, and immune
responses [5,6]. Several studies demonstrated that in naïve animals
Phlebotomus papatasi and L. longipalpis saliva inhibit IFN-γ and enhance
IL-4 and IL-10 secretion by Th1 and Th2 lymphocytes, respectively
[7–9]. We previously demonstrated that L. longipalpis SGE inhibited
OVA-induced neutrophil migration in immunized mice, apparently as aology, Faculty of Medicine of
eirantes 3900, Ribeirão Preto,
x: +55 16 36332301.
n).
evier OA license.consequence of the inhibition of TNF-α and LTB4 release [10]. However,
the molecule responsible for these effects has not been identiﬁed.
At the moment, few components present in SGE of sand ﬂies have
been studied. It has been described that L. Longipalpis saliva contains
apyrase, an anti-platelet aggregation agent [11], and adenosine
deaminase, an enzyme which promotes the hydrolysis of adenosine,
an immunomodulatory molecule [12,13]. Another important protein
is maxadilan that besides its potent vasodilator effect, it also presents
immunomodulatory effects by increasing in vitro secretion of IL-10
and IL-6, while inhibits TNF-α production in macrophages and
reduces CD80/86 expression on murine dendritic cells [14–16]. How-
ever, maxadilan does not inhibit neutrophil migration induced by OVA
in sensitizedmice [10]. In recent years, Valenzuela and colleagues [17]
identiﬁed and isolated the most abundant salivary proteins from the
sand ﬂy L. Longipalpis using high-throughoutput approaches based
on massive cDNA sequencing, proteomics and bioinformatic efforts.
Thus, these studies have enabled the investigation of which SGE
constituents are responsible for its anti-inﬂammatory activities.
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autoimmune disorder, affecting mainly joints, with the crucial
involvement of neutrophils, T cells, B cells, macrophages-like and
ﬁbroblasts-like synoviocytes [18,19], besides cytokines as TNF-α, IL-
17 and IFN-γ [20,21]. These cytokines activate immune and structural
cells in the joints, thus, promoting them to release products that lead
to tissue destruction [22].
Among the different experimental arthritis models, the antigen-
induced arthritis [23] model is a useful model to investigate new
effective therapies, since it shows similar histopathologic and
immune features to human RA [24,25]. In this way, the present
study was designed to examine the effect and the mechanism of
SGE and its components in experimental AIA model. In addition, the
present study also aimed to identify the sand ﬂy salivary molecule
responsible for the inhibition of OVA-induced neutrophil migration
and the role of this salivary molecule in the antigen-induced arthritis
model.2. Materials and methods
2.1. Animals
Sex matched BALB/c weighing 18–22 g each were housed in
temperature-controlled rooms (22–25 °C) in the animal facility of
the School of Medicine of Ribeirão Preto, University of São Paulo,
São Paulo, Brazil, and received water and food ad libitum. The study
protocols were conducted in accordance with the ethical guidelines
of the School of Medicine of Ribeirao Preto, University of São Paulo
(São Paulo, Brazil).2.2. Procedures for OVA and mBSA-induced neutrophil migration
The method is original as previously described [26] and adapted
[27]. On day 0, mice received a single s.c. injection of OVA (100 μg)
or methylated bovine serum albumin (mBSA) (500ug) in 0.2 ml of
an emulsion containing 0.1 ml of PBS and 0.1 ml of complete Freund's
adjuvant (CFA). The mice were given booster injections of OVA/mBSA
in incomplete Freund's adjuvant (IFA) on days 7 and 14. On day 21
immunized animals were challenged with injection of PBS (mBSA
vehicle), saline (OVA vehicle), OVA (100 μg/animal; intra-peritoneally,
i.p.) or mBSA (10 μg/cavity; intraarticularly, i.a.), and neutrophil migra-
tion was determined 24 h after mBSA and 4 h after OVA challenge.
Groups of mice received SGE (0.3; 1 or 3 gland/10ul; i.v. route) 48 h
beforeOVA and 24 h beforemBSA-challenge. rLJM111, a protein puriﬁed
from SGE, (30, 100 or 300 ng/mouse; i.v. route)was given 15 min before
mBSA-challenge. Total cell counts were evaluated in a cell counter (ACT;
Beckman Coulter, Miami, FL) and differential cell counts performed on
cytocentrifuge slides (Cytospin 3; Shandon, Pittsburgh, PA) stained
with Rosenfeld. Results were expressed as the number of neutrophils
per cavity.2.3. Articular hypernociception evaluation
The articular hypernociception (pain) of the femur–tibial joint
was evaluated as previously described [28]. A nonnociceptive tip
probe with area size of 4.15 mm2 was used. An increasing perpendic-
ular force was applied to the central area of the hind paw to induce
ﬂexion of the femur–tibial joint, followed by paw withdrawn. The
electronic pressure-meter apparatus automatically recorded the
intensity of the force applied when the paw was withdrawn. The
test was repeated until 3 subsequently consistent measurements
(i.e. the variation among these measurements was less than 1 g).
The results were expressed as the ﬂexion elicited withdrawal thresh-
old in grams (g).2.4. Construction of DNA plasmids coding for L. longipalpis secreted salivary
proteins and its treatment in immunized mice
Transcripts coding for the most abundant salivary proteins from
the sand ﬂy L. longipalpis were cloned into the VR2001-TOPO vector
and puriﬁed as previously described [29]. Plasmids coding for
LJS169, LJS238, LJL4, LJM5, LJL17, LJL35, LJL17, LJS143, LJM10, LJL13,
LJM11, LJS169, LJM78, LJM111 or LJM114 and OVA-immunized mice
were injected with 50 μg of these DNA plasmids (intramuscular
route) in 50 μl of saline 48 h before OVA challenge. Empty plasmids
were injected as control.
2.5. Expression and HPLC puriﬁcation of His-tagged L. longipalpis salivary
protein LJM11
Salivary recombinant protein LJM111 (rLJM111) was produced
by transfecting 4000 ml FreeStyle™ 293-F cells (Invitrogen) with
500 μg of puriﬁed plasmid following the manufacturer's recommen-
dations (Invitrogen). After 72 h, transfected cell cultures were
harvested and the supernatant ﬁltered through a 0.45 μM ﬁlter unit
and concentrated to 30 ml in anAmiconR concentrator device (Millipore
Corp., Bedford, MA, USA) in the presence of Buffer A (20 mMNaH2PO4,
20 mM Na2HPO4, pH 7.4 and 500 mM NaCl). A HiTrapTMChelating HP
column (GE Healthcare) was charged with 5 ml of Ni2SO4 0.1 M. The
concentrated recombinant protein was then added to the HiTrap
Chelating HP column. The column was then connected to a Summit
station HPLC system (Dionex) consisting of a P680 HPLC pump and a
PDA-100 photodiode array detector. The column was equilibrated for
30 min with Buffer A at 1 ml/min. After equilibration of baseline the
following gradient was used to elute the protein: minute 0–10 , 100%
Buffer A; minute 10–20, 0% buffer A, 100% Buffer B (20 mM NaH2PO4,
20 mMNa2HPO4, pH 7.4, 500 mMNaCl and 50 mM imidazole); minute
20–30 100%B; minute 30–60 a gradient of 100% B to 100%C (20 mM
NaH2PO4, 20 mMNa2HPO4, pH 7.4, 500 mMNaCl and 500 mM imidaz-
ole); minute 60–70 100% C. Eluted proteins were detected at 280 nm
and the eluted fractionswere collected everyminute on a 96wellmicro-
titer plate using a Foxy 200 fraction collector. All fractions were blotted
on a nitrocellulose paper and the blot was blocked with 5% milk for 1 h
and incubated for 1 hr with anti-saliva antibodies and 1 h with anti-
mouse Ap conjugated secondary antibody. Positive fractionswere devel-
oped with Wetern Blue stabilized substrate for alkaline phosphatase
(Promega). An aliquot (5 μl) of positive fractions were run on SDS and
silver stained using SilverQuest™ (Invitrogen). Imidazole was removed
from the positive fractions by dialysis against PBS, pH 7.4.
2.6. Enzyme-linked immunosorbent assay (ELISA)
Levels of IL-17, TNF-α and IFN-γ were quantiﬁed in vitro from
popliteal and inguinal lymph nodes cells (5×105 cells/well) pre-treated
or not with SGE (3 gland pairs/ml) or rLJM111 protein (2.7 μg/ml) and
stimulated with mBSA (100 μg/ml) or anti-CD3 (5 μg/ml) for 36 h by
ELISA. The results are expressed as picograms per milliliter.
2.7. DC generation
Dendritic cells (DC) were generated in vitro from bone marrow (BM)
cells from 6- to 8-wk-old wild type BALB/c as previously described [30].
Brieﬂy, femurs and tibias were ﬂushed with RPMI-1640 (Gibco-BRL Life
Technologies, Grand Island, NY) to release the BM cells thatwere cultured
in 24-well-culture plates in RPMI-1640 (Gibco) supplemented with 10%
heat-inactivated FCS, 100 μg/ml of penicillin, 100 μg/ml of streptomycin,
5×10−5 M 2-mercaptoethanol (all from Sigma), murine granulocyte-
macrophage colony-stimulating factor (GM-CSF) (30 ng/ml) and IL-4
(10 ng/ml) (Peprotech, Rocky Hill, NJ). On days 3 and 6 the supernatants
were gently removed and replaced with the same volume of supplemen-
tedmedium. On day 9, the non-adherent cells were collected to eliminate
Fig. 1. SGE and plasmids codifying to LJM 111 protein inhibited neutrophil migration
induced by OVA in immunized mice. (A) Immunized animals were treated with SGE
(1gl/mouse) or with vehicle control 48 h before intraperitoneal (i.p.) challenge with
OVA. (B) Immunized animals were treated 48 h before challenge with control plasmid
(C) or plasmids codifying to indicated proteins. The neutrophil migration was determined
4 h after PBS orOVA challenge in peritoneal cavity. Values are themean and SEMof 5mice.
* Pb0.05 versus saline injected immunized mice, # Pb0.05 versus immunized mice after
OVA challenge, by analysis of variance with Bonferroni adjustment.
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puriﬁed DC shows that in average 85% of cells express CD11cinterm or high
(marker of DC).
2.8. LPS-induced DC maturation
DCs (1×106 /ml) were incubated overnight with SGE (3 gland
pairs/ml), rLJM111 (2.7 μg/ml) or medium alone (RPMI 1640, 10%
FBS) at 37 °C in 5% CO2 and then followed by stimulation with or
without LPS (1 μg/ml) for 24 h. The cells were then harvested and
surface expression characterized by ﬂow cytometry using antibodies
against MHC class-II and CD86 conjugated to PE or FITC, as well as
isotype controls. Cytokines levels were measured into supernatant
of BMDC culture by ELISA assay.
2.9. Murine neutrophil isolation
Mouse neutrophils were isolated from bone marrow by Percoll
density gradient as previously described [31].
2.10. In vitro SGE or LJM 111 treatments
Neutrophils from BM of balb/c mice were treated with SGE (0.3; 1
or 3 gl/ml) or with LJM 111 protein (300, 900 or 2700 ng/ml) 30 min
before MIP-2 (30 ng/ml). Chemotaxis, actin polimerazition, and
CXCR2 and GRK-2 expression of neutrophils were performed as
described below.
2.11. Neutrophil chemotaxis
Chemotaxis was performed using a 48-well chemotaxis chamber
(Neuroprobe Inc) as previously described [31]. Neutrophils were
allowed to migrate 1 h toward MIP-2 (30 ng/ml, R&D Systems) or
medium alone (RPMI). After 1 h, the membrane was removed, ﬁxed,
and stained. Neutrophils that migrated through the membrane were
counted under a light microscope on at least 5 randomly selected
ﬁelds.
2.12. Actin polimerazition
Neutrophils were incubated with MIP-2 (30 ng/mL) at 37 °C for
5 min. Cells were ﬁxed, permeabilized, and stained with rhodamine-
phalloidin (Molecular Probes). Microscopic analysis of ﬂuorescent
images was performed using an Olympus BX40-F4 epiﬂuorescence
microscope. The mean ﬂuorescence density was determined from a
linear measurement of individual cells' ﬂuorescence. All cells of at
least 5 randomly chosen ﬁelds of each slide were analyzed.
2.13. CXCR2 and GRK-2 expression
For CXCR2 expression analysis, neutrophils were incubated with
phycoerythrin-conjugated anti-CXCR2 mAb and the cells were
washed, ﬁxed, and analyzed by ﬂow cytometry using a BD Biosciences
FACSort ﬂow cytometer. For GRK-2 expression analysis, neutrophils
were incubated with rabbit anti-mouse GRK2 Ab or isotype control
(Santa Cruz Biotechnology). Then Alexa-Fluor 594-conjugated goat
anti-rabbit IgG Ab (Invitrogen) were added. Microscopic analysis of
ﬂuorescent images was analyzed that was described above in
F-actin analysis.
2.14. Statistical analysis
Data are reported as the mean±SEM and are representative of 2 or
3 separate experiments with an n=5–6 per group in each experiment.
The means of different treatments were compared by analysis ofvariance with Bonferroni adjustment for multiple comparisons or by
Student's t-test. P values less than 0.05 were considered signiﬁcant.3. Results
3.1. The sand ﬂy salivary protein LJM111 mimics the anti-inﬂammatory
effects of saliva extract
L. longipalpis SGE inhibited neutrophil migration to peritoneal
cavity induced by OVA in immunized mice (Fig. 1A), conﬁrming
previous data published by our group [10]. Aiming to identify the
salivary proteins responsible for the anti-inﬂammatory effect, we
tested the effect of the main sand ﬂy secreted salivary proteins by
using plasmids coding for secreted proteins. Pre-treatment of OVA-
immunized mice with a plasmid coding to LJM111 protein, but not to
twelve other plasmids, inhibited neutrophil migration into peritoneal
cavity induced byOVA-challenge in immunizedmice (Fig. 1B), indicating
that LJM111 is the protein responsible for the powerful effect observed
with SGE. LJM111 is a protein of 43 kDa that belongs to the yellow family
of proteins identiﬁed in the saliva of sand ﬂies and in the midgut of the
mosquito Aedes aegypti and in the fruit ﬂy Drosophila. In order to verify
the activity observed on the plasmid coding for LJM111 protein, we
produced the recombinant protein LJM111 (rLJM111) in mammalian
cells. Both SGE and rLJM111 inhibited the neutrophil migration to artic-
ular cavity in a dose dependent manner (Fig. 2A and B, respectively)
Fig. 2. SGE and LJM 111 protein reduced neutrophil migration andmechanical hyperno-
ciception on AIA model. Prior to intraarticular (i.a.) challenge with mBSA, immunized
animals were treated 24 h before with 1 gl/mouse of SGE (A, C) or with recombinant
LJM 111 (30, 100 or 300 ng/mouse, 15 min before, B and D). (A and B) Neutrophil mi-
gration was evaluated 24 h after saline or mBSA challenge. (C and D) Hypernociception
was evaluated at the 1, 3, 5, 7 or 24 h after saline or mBSA challenge (30 μg/cavity).
Values are the mean and SEM of 5 mice. * Pb0.05 versus saline injected immunized
mice, # Pb0.05 versus immunized mice after mBSA challenge, by analysis of variance
with Bonferroni adjustment.
Fig. 3. SGE and LJM 111 inhibited inﬂammatory cytokines levels on lymph nodes cells.
Concentrations in vitro of IL-17, TNF-α and IFN-γ in supernatant from lymph nodes
cells treated or not with SGE (3 gl/ml) or protein LJM 111 (2700 ng/ml). The
concentrations of cytokines were determined 36 h after (A) mBSA (100 μg/ml) or
(B) anti-CD3 (10 μg/ml) stimuli. * Pb0.05 versus cells without stimulus, # Pb0.05
versus cells stimulated with anti-CD3 or mBSA, by analysis of variance with Bonferroni
adjustment.
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immunized mice (Fig. 2C and D, respectively).
3.2. Mechanismbywhich SGE and rLJM111 reduce inﬂammatory parameters
in immunized mice
Considering that pro-inﬂammatory cytokines are clearly involved
in neutrophil recruitment and mechanical hypernociception [32,33],
we investigated if SGE and rLJM111 can limit the release of pro-
inﬂammatory cytokines in lymph node cells of immunized mice stim-
ulated with mBSA or anti-CD3. Both SGE and rLJM111 inhibited IL-17,
TNF-α and IFN-γ production by lymph nodes cells induced by mBSA
in vitro (Fig. 3A), but did not reduce the cytokines levels from
lymph nodes cells stimulated with anti-CD3 (Fig. 3B). Thereafter,
we sought to investigate how SGE and rLJM111 may reduce the
Ag-induced cytokine release. It was observed that both SGE and
rLJM111 inhibited the expression of MHC-II and CD-86 in BMDCs
stimulated by LPS (Fig. 4A). Additionaly, SGE and rLJM111 reduced
TNF-α levels and increased IL-10 levels in supernatant of cultured
BMDC stimulated with LPS (Fig. 4B).
3.3. SGE, but not LJM 111, inhibits the chemotactic activity of neutrophils
obtained from mice
The neutrophil migration in vivo depends on the production of the
chemotactic mediators, which stimulate the neutrophil/endotelium
adhesion and neutrophil chemotaxis [32]. As shown in Fig. 5A, the
pretreatment of bone marrow neutrophils from mice with SGE, but
not LJM 111, reduced dose-dependently in vitro MIP-2-induced
chemotaxis. Moreover, SGE, but not the protein LJM 111, prevented
actin polymerization triggered by MIP-2 in these neutrophils
(Fig. 5B). These results prompted us to investigate more extensively
the mechanism by which SGE is negatively modulating the neutrophil
chemotaxis.
Thus, we veriﬁed that SGE reduced neutrophil CXCR2 expression
(Fig. 5C). Nextwe evaluated if the CXCR2 internalizationwas associated
to increased GRK2 expression, since the G protein-coupled receptorkinases (GRKs), regulatory molecules, are known to contribute to the
GPCR internalization process [34]. As shown in Fig. 5D, the SGE
enhanced neutrophil GRK2 levels. These results indicate that SGE
inhibits the neutrophil chemotaxis by promoting CXCR2 internalization
through the up-regulation of GRK2 expression. Besides, SGE also inhib-
ited chemotaxis of BM neutrophils unresponsive to LPS from HeJ mice
(supporting Fig. 1), thus, eliminating the possibility of LPS contamina-
tion as a cause for the observed effects.
4. Discussion
Considering the remarkable pre-clinical evidences that sand ﬂy SGE
regulates immune responses [1,8,9] and the importance of understand-
ing the pathogenic mechanisms involved in auto-immune diseases, we
investigated if sand ﬂy SGE could have anti-inﬂammatory effects in an
experimental model of arthritis. Our results show that SGE strongly
reduces neutrophil migration and pain sensitivity in the AIA model.
Importantly, this experimental models has several features observed
in the actual human RA disease [25].
SGE has several componentes and accordingly we attempted to
identify those responsible for the proeminent anti-inﬂammatory
effects in experimental AIA. Valenzuela and colleagues [17] identiﬁed
the most abundant secreted proteins from the salivary glands of the
sand ﬂy Lutzomyia longipalpis, thus, providing the experimental con-
ditions to determine the proteins which could be promoting these
Fig. 4. SGE and LJM 111 reduced CD86, MHC-II expression and TNF-α levels and enhance
IL-10 levels on dendritic cells. (A) Flow cytometry of CD86 and MHC-II expression and
(B) enzyme-linked immunosorbent assay to measurement of TNF- and IL-10 levels
following or not SGE (3.0 gl/ml) or LJM 111 (2700 ng/ml) treatment on dendritic cells
(DC) stimulatedwith LPS (1 μg/ml) per 24 h. The control group (C) received only medium.
* Pb0.05 versus untreated control, # Pb0.05 versus DC cells stimulatedwith LPS, by analy-
sis of variance with Bonferroni adjustment.
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mice with a plasmid containing a gene that codiﬁes for the salivary
protein LJM111, inhibited neutrophil migration to peritoneal cavity
in OVA-challenged immunized mice. Extending such ﬁnding, the
rLJM111 also reduced neutrophil recruitment and pain sensitivity in
AIA. This protein is a novel protein belonging to the family of
yellow-related protein of unknown function [17] and similar to
Ae. aegypti midgut dopachrome conversion enzyme [35] and D.
melanogaster yellow protein [36], suggesting that this protein may
be altering some tryptophane metabolite. LJM111 is a protein of
43.2 kDa that belongs to the yellow family of proteins. The structure
of LJM111 was recently modeled from the crystal structure of LJM11
another member of the yellow related family of proteins from sand
ﬂies. The structure of LJM111 is predicted to be of a six-bladed
β-propeller fold with a single ligand binding pocket for bioamines
located in the center of the propeller structure on one face of the
molecule [37]. Importantly to note is that the face of the structure
of LJM111 molecule is not charged as comparison to LJM11 which is
positively charged. Furthermore, the isoelectric point of LJM111 is
4.7 while the one for LJM11 is 9.3. LJM11 is very antigenic while
LJM111 is not [37]. It important to note that immunization with
LJM111 did not produce antibodies or cellular immune response in
mice [37], hamsters [38] or dogs [39]. Furthermore, dogs and humans
exposed to Lutzomyia longipalpis bites did not mount an antibody
response to LJM111 but mounted a very strong antibody response
to LJM11 [40]. This lack of antigenicity is in agreement with the prop-
erties of LJM111 described in the current work. It is noteworthy that
previous studies from our laboratory have discarded Maxadilan, a
powerful vasodilatory peptide with immunomodulatory properties
[14,41,42] present in SGE, as the protein responsible for these effectssince, maxadilan did not reproduce the effects of SGE in inhibiting
neutrophil migration in OVA-challenged immunized mice [10].
DCs play a central role in initiation of autoimmunity through
their capacity to present self antigens to T cells [43–45]. This role
depends on cytokine production and expression of co- and stimula-
tory surface molecules by these cells during antigen presentation
[46,47]. SGE and rLJM111 modulated the phenotypic and functional
maturation of DCs. Our results show that SGE and rLJM111 impair
the complete maturation of DCs stimulated with LPS, leading to
increased IL-10 production and reduced synthesis of TNF-α. This
cytokine production proﬁle was accompanied by a reduced expres-
sion of MHC-II and CD86. These results are of great interest since
immature or incompletely matured DCs can prevent autoimmunity
[48,49]. Previous reports have demonstrated that injections of
incompletely-matured DCs are able to induce IL-10 producing
CD4+ T cells and to prevent EAE in mice [48]. DCs overexpressing
IL-10 induce antigen-speciﬁc tolerance in experimental autoimmune
myocarditis [50]. Moreover, TNF-α can improve functional maturation
of DCs, selectively stimulating their capacity to induce Th1 responses,
while IL-10 is widely known to be an immunosuppressive cytokine
[51–53].
In line with these results, we also demonstrated that cells
obtained from lymph nodes of immunized mice and treated with
SGE or rLJM111 and stimulated with mBSA, but not with anti-CD3,
have a remarkable reduction of IL-17, TNF-α and IFN-γ production.
In fact, IL-17- and IFN-γ-secreting T cells have been associated with
the induction of many autoimmune diseases [54,55] and DCs play a
pivotal role in these processes [43,45]. IL-17 is directly implicated in
the severity of the cartilage and bone damage in an experimental
model of rheumatoid arthritis [56,57]. On the other hand, IL-17-
deﬁcient animals develop experimental autoimmune encephalomy-
elitis with delayed onset and diminished severity [58] and IL-17 and
IFN-γ had been implicated in the development of autoimmunity.
Mice deﬁcient for the transcription factors involved in the differenti-
ation of IFN-γ-secreting T cells, such as T-bet, are resistant to the
development of EAE [59]. The molecular mechanism by which
LJM111modulates DC function andmaturation is under investigation.
The excessive inﬂammatory responses in RA is associated with
activation of G protein coupled receptors (GPCRs) by pro-
inﬂammatory agonists as chemokines and prostaglandins [60,61].
It is well recognized that the responsiveness of these receptors
is actively ‘turned off’ by members of the G-protein-coupled
receptor kinase (GRK) [62,63]. In the context of disease, there are
reports in the literature showing that in RA patients and in rats after
development of adjuvant arthritis or experimental autoimmune
encephalomyelitis the levels of GRK2, 3, and 6 are reduced in leukocytes
from the blood or spleen [64–66]. This feature could be responsible at
least in part for the outcome of these diseases since GRK induces, for
instance, the internalization of CXCR2 receptors present in neutrophils,
which are necessary for their chemoattraction to the inﬂammatory foci
where neutrophils promote tissue destruction via metalloproteinases
and boost cytokine production [31]. Herein, we have demonstrated
that SGE provoked either CXCR2 internalization or improved GRK2
expression in neutrophils. This also leads to at least two possibilities:
1) It has been demonstrated in a monocytic human cell line that aden-
osine induces the internalization of adenosine A2A receptors upon
binding by a mechanism related to increased GRK2 expression, which
is a model of ligant binding-induced internalization. On the other
hand, TNFα reduces GRK2 expression, therefore, reducing the internal-
ization of A2A receptors [67]. Considering that SGE inhibited the
production of TNFα in lymphonode cells and dendritic cells, it is also
possible that SGE would inhibit a basal production of TNFα by neutro-
phils induced by the isolation process. It is consensus that there is
some basal activation of neutrophil during isolation; and/or 2) It is
possible that the SGE presents an unidentiﬁed molecule that induces
GRK2 expression and G protein coupled receptor internalization.
Fig. 5. The SGE, but not LJM 111 protein, inhibited in vitro neutrophil chemotaxis and actin polymerization, and SGE reduced CXCR2 expression and improved GRK-2 expression on
neutrophils. (A) Chemotaxis of BM neutrophils to MIP-2 after 30 min SGE (0.3, 1.0 or 3.0 glands/ml) or LJM 111 (300, 900 or 2700 ng/ml) treatment. (B) F-actin polymerization of
BM neutrophils to MIP-2 (30 ng/ml) after SGE (3.0 gland/ml) or LJM 111 (2700 ng/ml) treatment. Representative images (above) and quantiﬁcation of F-actin polymerization by
mean ﬂuorescence density (below) are shown. (C) Flow cytometry of neutrophil CXCR2 expression and (D) immunoﬂuorescence of GRK2 expression following SGE (3.0 glands/ml)
treatment quantiﬁed by mean ﬂuorescence intensity (MFI, below) and representative immunoﬂuorescence microphotograph of GRK2 expression (above). *=Pb0.05 versus
control group (C); #=Pb0.05 versus group of neutrophils stimulated with MIP-2, by analysis of Student's t-test or one-way ANOVA where appropriate.
608 R. Grespan et al. / International Immunopharmacology 12 (2012) 603–610However, rLJM111 does not present this direct effect on
neutrophils, indicating that other constituint(s) of SGE are responsible
for the GRK-dependent downregulation of CXCR2 expression in neutro-
phil. In fact, rLJM111 inhibited the production of inﬂammatory media-
tors that are chemoattractants of neutrophils such as TNFα and IL-17.
The result demonstrating that LJM111 did not affect the chemoattrac-
tion induced by MIP-2 further corroborates the suggestion that
LJM111 inhibits the production of inﬂammatory molecules resulting
in reduced in vivo neutrophil recruitment, but does not affect the effect
of inﬂammatory molecules already produced resulting in absence of
effect in the chemoattraction in vitro assay inwhich the activemolecule
is added without the need of a resident cell production. Thus, the saliva
property of downregulating the inﬂammation justify further efforts to
investigate the components responsible for this effect.5. Conclusions
We showed that one of the mechanisms triggered by SGE and
rLJM111 to inhibit the inﬂammatory response induced by mBSA could
be by the modulation of DC function and maturation. SGE presents an
additional property, which is not shared by LJM111, the inhibition of
neutrophil chemotaxis a GRK-dependent downregulation of CXCR2
expression in a TLR4-independent mechanism. Therefore, LJM 111
protein, present in SGE, partially accounts for SGE anti-inﬂammatory
activity in AIA model by modulating DC function and maturation but
not acute innate inﬂammatory responses (neutrophil chemotaxis).
This relative limitation of LJM111 mechanism compared to SGE does
not reduce the importance of the ﬁnding. In fact, it increases its possible
clinical relevance since in auto-immune diseases such as RA, it is desire-
ble to inhibit auto-immune responses without affecting innate inﬂam-
matory responses necessary for host defence against infections.Furthermore, these results demonstrate the importance of distinguising
the molecules present in SGE and their mechanisms.
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.intimp.2012.02.004.
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